Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Larysa Sanchez, MD; and Samantha Shenoy, MSN, NP, discuss the management of adverse events with bispecific antibodies like GPRC5D and talquetamab while providing guidance on optimizing treatment outcomes and supportive care, as well as offering advice for managing toxicities and future perspectives on relapsed/refractory multiple myeloma.
Neoadjuvant TAR-200/Cetrelimab Combo Generates Responses in Muscle-Invasive Bladder Cancer
Adding Relatlimab to Nivolumab/Chemo Did Not Increase Toxicity
Hypofractionated Radiation Noninferior for Lymphedema Prevention in Early Breast Cancer
Perioperative Durvalumab With Neoadjuvant Chemo Boosts Survival in Cisplatin-Eligible MIBC